|
[Related PubMed/MEDLINE]
Total Number of Papers: 92
|
|
|
|
|
[Display Entries]
|
| |
|
[Entries Per Page]
|
|
per page
|
| |
|
Page Control
|
|
|
|
Page: of
|
|
|
|
| Abbreviation |
: LA |
| Long Form |
: lipoprotein apheresis |
|
| No. |
Year |
Title |
Co-occurring Abbreviation |
| 1 |
2019 |
A complicated pregnancy in homozygous familial hypercholesterolaemia treated with lipoprotein apheresis: A case report. |
HoFH, LDL-C, NSTEMI, TC |
| 2 |
2019 |
A cross-national investigation of cardiovascular survival in homozygous familial hypercholesterolemia: The Sino-Roman Study. |
CVD, HoFH, LDL |
| 3 |
2019 |
Actual situation of lipoprotein apheresis in patients with elevated lipoprotein(a) levels. |
GWAS, LDL-C |
| 4 |
2019 |
Coronary computed tomography angiography and echocardiography in children with homozygous familial hypercholesterolemia. |
CCTA, HoFH, LDL-C |
| 5 |
2019 |
Effect of evolocumab on lipoprotein apheresis requirement and lipid levels: Results of the randomized, controlled, open-label DE LAVAL study. |
LDL-C |
| 6 |
2019 |
Efficacy and safety of lipoprotein apheresis in children with homozygous familial hypercholesterolemia: A systematic review. |
CVD, HoFH, LDL-C |
| 7 |
2019 |
Experience with proprotein convertase subtilisin/kexine type 9 inhibitors (PCSK9i) in patients undergoing lipoprotein apheresis. |
LDL-C, PCSK9i |
| 8 |
2019 |
Improvement of oxidative stress status by lipoprotein apheresis in Chinese patients with familial hypercholesterolemia. |
FH, FORD, FORT, OS |
| 9 |
2019 |
Influence of lipoprotein apheresis on circulating plasma levels of miRNAs in patients with high Lp(a). |
miRNAs |
| 10 |
2019 |
Lipoprotein apheresis efficacy, challenges and outcomes: A descriptive analysis from the UK Lipoprotein Apheresis Registry, 1989-2017. |
HeFH, HoFH, MACE |
| 11 |
2019 |
Lipoprotein apheresis for lipoprotein(a) and cardiovascular disease. |
CVD, LDL-C |
| 12 |
2019 |
Lipoprotein apheresis in Germany - Still more commonly indicated than implemented. How can patients in need access therapy? |
CAD, CVD, LDL-C |
| 13 |
2019 |
Lipoprotein apheresis is an optimal therapeutic option to reduce increased Lp(a) levels. |
ASCVD, CVD, GLAR, LDL-C, MACE, MANCE |
| 14 |
2019 |
Lipoprotein(a)-an interdisciplinary challenge. |
CVE, PCSK9 |
| 15 |
2019 |
Looking at Lp(a) and Related Cardiovascular Risk: from Scientific Evidence and Clinical Practice. |
EMA, HDL, LDL |
| 16 |
2019 |
NMR-based lipoprotein analysis for patients with severe hypercholesterolemia undergoing lipoprotein apheresis or PCSK9-inhibitor therapy (NAPALI-Study). |
HDL-C, LDL-C, LDL-P, PCSK9 |
| 17 |
2019 |
Optical coherence tomography of retinal and choroidal layers in patients with familial hypercholesterolaemia treated with lipoprotein apheresis. |
BVCA, ChT, CMT, FAZ, FH, IOP, OCT, OCTA, SE, VD |
| 18 |
2019 |
Pleiotropic Effect of Lipoprotein-Apheresis on the Soluble Form of Activated Leukocyte Cell Adhesion Molecule (sALCAM) in Familial Hypercholesterolaemia. |
ALCAM, LDL-C, PRR, sALCAM |
| 19 |
2019 |
Real-World Outcomes with Lomitapide Use in Paediatric Patients with Homozygous Familial Hypercholesterolaemia. |
ASCVD, HoFH, LDL-C |
| 20 |
2019 |
Real-world study: Escalating targeted lipid-lowering treatment with PCSK9-inhibitors and lipoprotein apheresis. |
ASCVD, LLT, PCSK9, TEAE |
| 21 |
2019 |
Role of Lipoprotein Apheresis in Cardiovascular Disease Risk Reduction. |
CVD, FH |
| 22 |
2019 |
Short- and long-term effects of lipoprotein apheresis on plasma hormones in patients with therapy-resistant dyslipidemia. |
DALI, DSA, LF, MONET |
| 23 |
2018 |
A nation-wide survey of patients with homozygous familial hypercholesterolemia phenotype undergoing LDL-apheresis in Turkey (A-HIT 1 registry). |
HoFH, LDL-C |
| 24 |
2018 |
Current Role of Lipoprotein Apheresis in the Treatment of High-Risk Patients. |
CVE |
| 25 |
2018 |
High serum triglyceride concentrations in patients with homozygous familial hypercholesterolemia attenuate the efficacy of lipoprotein apheresis by dextran sulfate adsorption. |
DSA, HELP, HoFH |
| 26 |
2018 |
Impact of lipoprotein apheresis with dextran-sulfate adsorption on the expression of genes involved in cardiovascular health in the blood of patients with homozygous familial hypercholesterolemia. |
BCL3, DSA, Egr, HoFH |
| 27 |
2018 |
Improvement of refractory pruritus after lipoprotein-apheresis in arthrogryposis-renal failure-cholestasis syndrome. |
TBA |
| 28 |
2018 |
Lipoprotein Apheresis and PCSK9-Inhibitors. Impact on Atherogenic Lipoproteins and Anti-Inflammatory Mediators in Familial Hypercholesterolaemia. |
HeFH, HoFH, PCSK9-I |
| 29 |
2018 |
Lipoprotein-apheresis in familial hypercholesterolemia: Long-term patient compliance in a French cohort. |
--- |
| 30 |
2018 |
Long-term lipoprotein apheresis in the treatment of severe familial hypercholesterolemia refractory to high intensity statin therapy: Three year experience at a lipoprotein apheresis centre. |
DALI, FH, HDL-C, HeFH, IAS, LDL-C, MONET, TC, TG |
| 31 |
2018 |
Management of homozygous familial hypercholesterolaemia in two brothers. |
HoFH, LDL-C |
| 32 |
2018 |
Multimodal lipid-lowering treatment in pediatric patients with homozygous familial hypercholesterolemia-target attainment requires further increase of intensity. |
chet, CVD, FH, HO, LDL-C, LLT, PCSK9 |
| 33 |
2018 |
Reduced incidence of cardiovascular events in hyper-Lp(a) patients on lipoprotein apheresis. The G.I.L.A. (Gruppo Interdisciplinare Aferesi Lipoproteica) pilot study. |
ACVE |
| 34 |
2018 |
Treatment-related and health-related quality of life in lipoprotein apheresis patients. |
HRQOL, QOL |
| 35 |
2018 |
Vascular access in lipoprotein apheresis: a retrospective analysis from the UK's largest lipoprotein apheresis centre. |
AV, LDL |
| 36 |
2017 |
Barriers to the Implementation of Lipoprotein Apheresis in Canada. |
HoFH |
| 37 |
2017 |
Case report of male child with elevated lipoprotein (a) leading to acute ischemic stroke. |
AIS |
| 38 |
2017 |
Current insights into the German Lipoprotein Apheresis Registry (GLAR) - Almost 5 years on. |
CVD, GLAR, LDL-C |
| 39 |
2017 |
Current insights into the German lipoprotein apheresis standard: PCSK9-inhibitors, lipoprotein apheresis or both? |
PCSK9-I |
| 40 |
2017 |
Dysregulation of the CD4+ T cells lineage differentiation in dyslipidemic patients and impact of lipoprotein-apheresis treatment: A case study. |
--- |
| 41 |
2017 |
Efficacy of Lomitapide in the Treatment of Familial Homozygous Hypercholesterolemia: Results of a Real-World Clinical Experience in Italy. |
HoFH, LLT, MRS |
| 42 |
2017 |
H.E.L.P apheresis exerts long term effects on the capacity of circulating proangiogenic cells. |
CV, HELP, PAC, SDF-1 |
| 43 |
2017 |
How effectively will PCSK9 inhibitors allow retrieval of freedom from apheresis in cardiovascular high risk patients? - Estimates form a large single center. |
LDL-C, PCSK-9 |
| 44 |
2017 |
Hyperlipoproteinaemia(a) - apheresis and emerging therapies. |
CVD, LDL-C |
| 45 |
2017 |
Kinetics of Lipoprotein(a) in patients undergoing weekly lipoprotein apheresis for Lp(a) hyperlipoproteinemia. |
--- |
| 46 |
2017 |
Lipoprotein apheresis downregulates IL-1alpha, IL-6 and TNF-alpha mRNA expression in severe dyslipidaemia. |
CAD, mRNA |
| 47 |
2017 |
Lipoprotein apheresis in patients with peripheral artery disease and lipoprotein(a)-hyperlipoproteinemia: 2-year follow-up of a prospective single center study. |
ABI, PAD, VAS |
| 48 |
2017 |
Lipoprotein apheresis influences monocyte subpopulations. |
--- |
| 49 |
2017 |
Lipoprotein(a)-hyperlipoproteinemia as cause of chronic spinal cord ischemia resulting in progressive myelopathy - successful treatment with lipoprotein apheresis. |
CAD, CVD, PAOD |
| 50 |
2017 |
Most significant reduction of cardiovascular events in patients undergoing lipoproteinapheresis due to raised Lp(a) levels - A multicenter observational study. |
CV |
| 51 |
2017 |
Prevention of cardiovascular complications in patients with Lp(a)-hyperlipoproteinemia and progressive cardiovascular disease by long-term lipoprotein apheresis according to German national guidelines. |
CVD, HLP, MACE |
| 52 |
2017 |
Prospective crossover study for a standardized comparison of the dextrane sulfate whole blood and plasma apheresis system in patients with cardiovascular disease and severe dyslipidemia. |
--- |
| 53 |
2017 |
Rationale and design of MultiSELECt: A European Multicenter Study on the Effect of Lipoprotein(a) Elimination by lipoprotein apheresis on Cardiovascular outcomes. |
CVD, LDL-C |
| 54 |
2017 |
The German Lipoprotein Apheresis Registry (GLAR) - almost 5years on. |
CVD, GLAR |
| 55 |
2017 |
Toward an international consensus-Integrating lipoprotein apheresis and new lipid-lowering drugs. |
--- |
| 56 |
2016 |
Lipoprotein Apheresis for Lipoprotein(a)-Associated Cardiovascular Disease: Prospective 5 Years of Follow-Up and Apolipoprotein(a) Characterization. |
--- |
| 57 |
2016 |
Lipoprotein apheresis in the management of severe hypercholesterolemia and of elevation of lipoprotein(a): current perspectives and patient selection. |
HCh, LDL-C |
| 58 |
2016 |
Lipoprotein apheresis is essential for managing pregnancies in patients with homozygous familial hypercholesterolemia: Seven case series and discussion. |
HoFH |
| 59 |
2016 |
Lipoprotein apheresis reduces circulating galectin-3 in humans. |
DSA, Gal-3, HELP |
| 60 |
2016 |
Lipoprotein Apheresis. |
CVD, FH, LDL-C |
| 61 |
2016 |
Long-Term Follow-Up of a Homozygous Familial Hypercholesterolemic Patient Receiving Regular Double Filtration Plasmapheresis - Case Report and Literature Review. |
DFPP, HoFH, LDL, LDL-C |
| 62 |
2016 |
Management of homozygous familial hypercholesterolemia in real-world clinical practice: A report of 7 Italian patients treatedinRome with lomitapide and lipoproteinapheresis. |
AEs, HoFH, LDL-C |
| 63 |
2016 |
Quality of life in patients treated with lipoprotein apheresis. |
BDI, CVD, LDL-C, QOL |
| 64 |
2016 |
Ten years of lipoprotein apheresis for familial hypercholesterolemia in Malaysia: A creative approach by a cardiologist in a developing country. |
FH |
| 65 |
2016 |
The role of lipoprotein(a) in clotting reactions during lipoprotein apheresis--A case report. |
FH |
| 66 |
2016 |
Validation of a new method for non-invasive assessment of vasomotor function. |
COV, FH, FMD, FMS, PWV |
| 67 |
2015 |
Actual situation of lipoprotein apheresis in Saxony in 2013. |
CVE, HoFH, non-HDL-C, TG, UHD |
| 68 |
2015 |
Clinical benefit of long-term lipoprotein apheresis in patients with severe hypercholesterolemia or Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease. |
CVD, LDL-C |
| 69 |
2015 |
Detailed description of the cardiovascular situation in patients who have started lipoprotein apheresis treatment. |
CVE, LDL-C |
| 70 |
2015 |
Effects of different lipoprotein apheresis methods on serum protein levels. |
--- |
| 71 |
2015 |
Effects of lipoprotein apheresis on PCSK9 levels. |
LDL-C, LDLR |
| 72 |
2015 |
Effects of Lipoprotein apheresis on the Lipoprotein(a) levels in the long run. |
--- |
| 73 |
2015 |
Efficacy, safety, and tolerability of long-term lipoprotein apheresis in patients with LDL- or Lp(a) hyperlipoproteinemia: Findings gathered from more than 36,000 treatments at one center in Germany. |
AE, CVD, LDL-C, MACE |
| 74 |
2015 |
Impact of the German Lipoprotein Apheresis Registry (DLAR) on therapeutic options to reduce increased Lp(a) levels. |
LDL-C, MACE, MANCE |
| 75 |
2015 |
Increasing plasma lysophosphatidylcholine levels in patients with regular dextran sulfate lipoprotein apheresis. |
DSA, LPC, PE |
| 76 |
2015 |
Lipoprotein apheresis for Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease--Additional particular aspects of the Pro(a)LiFe multicenter trial. |
CVD |
| 77 |
2015 |
Lipoprotein apheresis in patients with peripheral artery disease and hyperlipoproteinemia(a). |
ABI, PAD |
| 78 |
2015 |
Lipoprotein apheresis results in plaque stabilization and prevention of cardiovascular events: comments on the prospective Pro(a)LiFe study. |
HLP, LDL |
| 79 |
2015 |
Lipoprotein apheresis. |
CVD, FH, LDL-C |
| 80 |
2015 |
Mental symptoms and quality of life in lipoprotein apheresis patients in comparison to hemodialysis patients, platelet donors and normal population. |
CAQ, HADS, HD, HRQL, NP |
| 81 |
2015 |
The incidence of cardiovascular events is largely reduced in patients with maximally tolerated drug therapy and lipoprotein apheresis. A single-center experience. |
ACVE, FCH, FH |
| 82 |
2015 |
TIDILAP: Treatment of iron deficiency in lipoprotein apheresis patients --A prospective observational multi-center cohort study comparing efficacy, safety and tolerability of ferric gluconate with ferric carboxymaltose. |
FCM, FG, ID, IDA |
| 83 |
2015 |
Treating homozygous familial hypercholesterolemia in a real-world setting: Experiences with lomitapide. |
HoFH, LDL-C, LLTs, MTP |
| 84 |
2015 |
[Position of lipoprotein apheresis in present]. |
FH, LDL |
| 85 |
2014 |
LDL-apheresis dramatically improves generalized calciphylaxis in a patient undergoing hemodialysis. |
SPP |
| 86 |
2014 |
Lipoprotein apheresis reduces biomarkers of plaque destabilization and cardiovascular risk. |
--- |
| 87 |
2013 |
How to optimize lipoprotein apheresis treatment--a second look. |
BV, LDL-C |
| 88 |
2013 |
Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study. |
--- |
| 89 |
2013 |
Lipoprotein apheresis: state of the art and novelties. |
CVR, LDL, PEX |
| 90 |
2013 |
Loss of plasma proprotein convertase subtilisin/kexin 9 (PCSK9) after lipoprotein apheresis. |
FH, LDL, PCSK9 |
| 91 |
2004 |
Impact of regular LDL apheresis on the development of restless legs syndrome. |
RLS |
| 92 |
0 |
The role of PCSK9-inhibitors and of lipoprotein apheresis in the treatment of homozygous and severe heterozygous familial hypercholesterolemia: A rivalry, or are things quite different? |
FH, LDL, LDL-C, PCSK9 |
|
A Search Service for Abbreviation / Long Form
